From Medscape Rheumatology

Coverage from the

Canadian Rheumatology Association (CRA) 2023 Annual Meeting

February 08 - 11, 2023; Québec City, Canada, and Virtual

February 08 - 11, 2023 Québec City, Canada, and Virtual

CRA 2023 Biosimilars, Originators Have Near Identical Stop Rates A real-world analysis of the impact of biosimilar switches over 3 years of follow-up addresses the limitations of formal trials in assessing discontinuation rates.
MDedge News, February 14, 2023

Conference News

CRA 2023 New Tool Better Estimates CV Risk in People With Lupus
MDedge News, February 16, 2023
CRA 2023 PsA Prediction Tool Approaches Clinical Utility
MDedge News, February 16, 2023

CRA 2023 Two Biomarkers Identify High-Risk Lupus Nephritis
MDedge News, February 14, 2023
CRA 2023 Biosimilars, Originators Have Near Identical Stop Rates
MDedge News, February 14, 2023

Disclaimer

Credits:

Lead image: Vlad Ghiea/Dreamstime

Medscape Rheumatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News from CRA 2022

JAK Inhibitors' Warning Belies Durability in Registry Studies JAK inhibitors' discontinuation and retention rates were similar to those for biologic disease-modifying antirheumatic drugs in large Canadian RA data sets.
Medscape Medical News, Feb 09, 2022
Real-World Data Back Stem Cell Transplant for Systemic Sclerosis In real-world study, stem cell transplant provides major advantages for rapidly progressive systemic sclerosis if strict selection criteria are used.
Medscape Medical News, Feb 08, 2022
Guselkumab Controls Axial Involvement in PsA Through 2 Years In psoriatic arthritis patients with axial involvement, researchers saw sustained improvement with guselkumab through 100 weeks on all outcomes employed to evaluate change in axial symptoms.
Medscape Medical News, Feb 10, 2022

Related Coverage

Related Resources